Stem Cells vs Exosomes: Key Differences, FDA Considerations, and Insurance Risks for Clinics and Biologics Companies
News & Posts Stem Cells vs Exosomes: Key Differences, FDA Considerations, and Insurance Risks for Clinics and Biologics Companies The distinction between stem cells and
White Label, Private Label, and Distribution Risk: Product Liability Insurance in Regenerative Medicine
News & Posts White Label, Private Label, and Distribution Risk: Product Liability Insurance in Regenerative Medicine White label and private label models in regenerative medicine
Product Liability Insurance for Regenerative Medicine Companies: What Manufacturers, Distributors, and Biologics Brands Need to Know
News & Posts Product Liability Insurance for Regenerative Medicine Companies: What Manufacturers, Distributors, and Biologics Brands Need to Know Product liability insurance for regenerative medicine
FDA Scrutiny, Product Claims, and Product Liability Insurance in Regenerative Medicine
News & Posts FDA Scrutiny, Product Claims, and Product Liability Insurance in Regenerative Medicine FDA scrutiny substantially reshapes the liability landscape for regenerative medicine companies.
PRP and the FDA: How Advertising Claims Can Trigger Regulatory Risk for Regenerative Clinics
News & Posts PRP and the FDA: How Advertising Claims Can Trigger Regulatory Risk for Regenerative Clinics PRP therapy is often viewed as presenting lower
FDA Oversight of Ozone Therapy: Documentation Standards Every Regenerative Clinic Should Understand
News & Posts FDA Oversight of Ozone Therapy: Documentation Standards Every Regenerative Clinic Should Understand The FDA’s classification of ozone as a toxic gas poses
351 vs 361 HCT/P Rules: How FDA Classification Determines the Survival of Regenerative Clinics
News & Posts 351 vs 361 HCT/P Rules: How FDA Classification Determines the Survival of Regenerative Clinics The classification of HCT/P products under Section 351
Navigating Insurance For Non-FDA-Approved Therapies: How Integrative And Regenerative Clinics Can Qualify For Coverage
News & Posts Navigating Insurance For Non-FDA-Approved Therapies: How Integrative And Regenerative Clinics Can Qualify For Coverage In the evolving landscape of healthcare, integrative and
From PRP To Peptides: Inside The Risk Framework Insurers Use For Emerging Regenerative Treatments
News & Posts From PRP To Peptides: Inside The Risk Framework Insurers Use For Emerging Regenerative Treatments As burgeoning regenerative therapies such as Platelet-Rich Plasma
Understanding Underwriting Criteria For Off-Label And Experimental Medical Procedures: What Providers Need To Know
News & Posts Understanding Underwriting Criteria For Off-Label And Experimental Medical Procedures: What Providers Need To Know The significance of underwriting criteria in the context